These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38472557)

  • 21. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.
    Marchini S; Cavalieri D; Fruscio R; Calura E; Garavaglia D; Fuso Nerini I; Mangioni C; Cattoretti G; Clivio L; Beltrame L; Katsaros D; Scarampi L; Menato G; Perego P; Chiorino G; Buda A; Romualdi C; D'Incalci M
    Lancet Oncol; 2011 Mar; 12(3):273-85. PubMed ID: 21345725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.
    Yu X; Zhang X; Bi T; Ding Y; Zhao J; Wang C; Jia T; Han D; Guo G; Wang B; Jiang J; Cui S
    Tumour Biol; 2013 Dec; 34(6):3501-8. PubMed ID: 23836287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment.
    Al-Khanbashi M; Caramuta S; Alajmi AM; Al-Haddabi I; Al-Riyami M; Lui WO; Al-Moundhri MS
    PLoS One; 2016; 11(4):e0152032. PubMed ID: 27064979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
    Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
    Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer.
    Gao YC; Wu J
    Tumour Biol; 2015 Jun; 36(6):4843-50. PubMed ID: 25636451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy.
    Niwa Y; Yamada S; Sonohara F; Kurimoto K; Hayashi M; Tashiro M; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Kodera Y
    J Transl Med; 2019 Jan; 17(1):1. PubMed ID: 30602370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma.
    Samimi G; Ring BZ; Ross DT; Seitz RS; Sutherland RL; O'Brien PM; Hacker NF; Huh WK
    Cancer Epidemiol Biomarkers Prev; 2012 Feb; 21(2):273-9. PubMed ID: 22194527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response.
    Xing AY; Wang B; Li YH; Chen X; Wang YW; Liu HT; Gao P
    Pathol Oncol Res; 2021; 27():1609753. PubMed ID: 34257614
    [No Abstract]   [Full Text] [Related]  

  • 29. Expression of serum miR-218 in hepatocellular carcinoma and its prognostic significance.
    Yang L; Xu Q; Xie H; Gu G; Jiang J
    Clin Transl Oncol; 2016 Aug; 18(8):841-7. PubMed ID: 26586116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ascites-Derived Extracellular microRNAs as Potential Biomarkers for Ovarian Cancer.
    Záveský L; Jandáková E; Weinberger V; Minář L; Hanzíková V; Dušková D; Drábková LZ; Svobodová I; Hořínek A
    Reprod Sci; 2019 Apr; 26(4):510-522. PubMed ID: 29779470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer.
    Su YY; Sun L; Guo ZR; Li JC; Bai TT; Cai XX; Li WH; Zhu YF
    J Ovarian Res; 2019 Jan; 12(1):6. PubMed ID: 30670062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
    Panoutsopoulou K; Avgeris M; Magkou P; Mavridis K; Dreyer T; Dorn J; Obermayr E; Reinthaller A; Michaelidou K; Mahner S; Vergote I; Loverix L; Braicu I; Sehouli J; Zeillinger R; Magdolen V; Scorilas A
    Int J Cancer; 2020 Dec; 147(12):3560-3573. PubMed ID: 32621752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel.
    Li Q; Liu M; Ma F; Luo Y; Cai R; Wang L; Xu N; Xu B
    PLoS One; 2014; 9(8):e104870. PubMed ID: 25137071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer.
    Meng X; Müller V; Milde-Langosch K; Trillsch F; Pantel K; Schwarzenbach H
    Oncotarget; 2016 Mar; 7(13):16923-35. PubMed ID: 26943577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer.
    Günel T; Gumusoglu E; Dogan B; Ertem FB; Hosseini MK; Cevik N; Senol T; Topuz S; Aydinli K
    Arch Gynecol Obstet; 2018 Dec; 298(6):1173-1180. PubMed ID: 30264202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer.
    Zhu W; Liu M; Fan Y; Ma F; Xu N; Xu B
    Cancer Med; 2018 Sep; 7(9):4420-4433. PubMed ID: 30099860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
    Wu WJ; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
    Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
    Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum miRNA-1 may serve as a promising noninvasive biomarker for predicting treatment response in breast cancer patients receiving neoadjuvant chemotherapy.
    Peng J; Lin Y; Sheng X; Yuan C; Wang Y; Yin W; Zhou L; Lu J
    BMC Cancer; 2024 Jul; 24(1):789. PubMed ID: 38956544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
    Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
    Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.